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Introduction: Case fatality among in-patients with HIV-associated
tuberculosis (HIV-TB) in Africa is high. We investigated the factors
associated with mortality in a rural South African hospital.
Methods: This was a prospective observational study of HIV-TB
in-patients, with death by 8 weeks the endpoint.
Results: Of 99 patients (median CD4 count 72 cells/mm3), 32 (32%)
died after median 8-day TB treatment. TB was diagnosed microbio-
logically in 75/99 and clinico-radiologically in 24, with no mortality
difference between these groups [31% versus 38% (P = 0.53)].
Median venous lactate was 5.5 mmol/L (interquartile range 3.9–6.2) in
those who died and 3.1 mmol/L (interquartile range 2.2–4.1) in
survivors (P , 0.001). In multivariable analysis, lactate $4 mmol/L
[adjusted odds ratio (aOR) 9.8, 95% conﬁdence interval (CI): 3.0 to
32.2], Glasgow Coma Score ,15 (aOR 6.6, 95% CI: 1.5 to 29.6),
CD4 count ,50 cells per cubic millimeter (aOR 5.5, 95% CI: 1.6 to
18.5), and age $50 (aOR 7.7, 95% CI: 1.2 to 46.9) independently
predicted death. In a nested case–control study, comparing those who
died versus CD4-matched survivors, median plasma lipopolysaccha-
ride concentrations were 93 and 57 pg/mL (P = 0.026) and intestinal
fatty acid–binding protein, 132 and 0 pg/mL (P = 0.002).
Conclusions: Mortality was high and predicted by elevated lactate,
likely reﬂecting a sepsis-syndrome secondary to TB or bacterial
coinfection with intestinal barrier dysfunction appearing to contribute.
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INTRODUCTION
Tuberculosis (TB) is the common cause of death among
HIV-infected individuals in sub-Saharan Africa.1–3 Public
health interventions demonstrated to reduce mortality in
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HIV-associated TB include timely antiretroviral therapy
(ART)4 and cotrimoxazole prophylaxis.5 Despite these, case
fatality rates during TB treatment remain high, particularly
among hospitalized patients.6,7
The direct cause of death is poorly deﬁned. Possible
mechanisms for death include septic shock due to dissemi-
nated TB,8 bacterial sepsis, other opportunistic infections, or
drug-resistant TB.
Autopsy studies have shown that bacterial infections
and cytomegalovirus (CMV) end organ disease are common.9
The association of bacterial product translocation with
mortality seen in patients with chronic liver disease10,11 may
be relevant in HIV-associated TB. Intestinal CD4 T-cell
depletion results in translocation of lipopolysaccharide (LPS)
and other bacterial products, contributing to immune activa-
tion during chronic HIV infection.12,13 We hypothesize that in
advanced HIV-associated TB, intestinal immunity and the
epithelial barrier may be profoundly impaired, leading to
heightened immune activation from bacterial product trans-
location contributing to a sepsis syndrome.
To improve acute management of in-patients, a greater
understanding of the pathophysiology of severe HIV-
associated TB is required. We conducted a prospective
observational study in a routine care setting in rural South
Africa, where the best estimate for national TB incident rates
was 993 per 100,000 population and HIV prevalence among
incident cases was recorded at 65% in 2011.14 We investi-
gated factors potentially associated with mortality, including
venous lactate and CMV viremia, to assess a novel hypothesis
that mortality is associated with biomarkers of intestinal
damage and translocation.
MATERIALS AND METHODS
Setting and Study Design
The study took place at Madwaleni Hospital, which is
situated in a deeply rural part of the Eastern Cape Province.
The hospital has 180 beds and serves approximately 120,000
people. Between May and October 2011, consecutive patients
were recruited fulﬁlling inclusion criteria of hospitalized, age
$18 years, HIV infection and a new diagnosis of active TB
on admission or #14 days before or after admission, and
blood samples taken within 14 days of starting TB treatment.
TB was conﬁrmed microbiologically or diagnosed clinico-
radiologically, reﬂecting clinical practice in this setting. A
nested case–control study assessed associations between
plasma LPS and intestinal fatty acid–binding protein (I-
FABP) and death: controls were survivors with the closest
subsequent enrollment date to each fatal case and CD4 count
within 50 cells per cubic millimeter of the case.
Clinical Management and Assessment
A TB symptom enquiry was performed on admission
for all patients with conﬁrmed or suspected HIV. If symp-
tomatic, a chest radiograph was performed and sputum
sample taken. TB and HIV were treated according to national
guidelines.15 Point-of-care HIV testing was offered to all with
suspected TB. HIV-infected individuals were referred for
ART, which was started within 2 weeks of TB treatment if
CD4 count #100/mm3 and within 8 weeks if CD4 count was
100–350/mm3. First-line ART was tenofovir, lamivudine, and
efavirenz. The routine practice in the hospital during the study
period was prescription of cotrimoxazole prophylaxis for all
patients diagnosed with HIV-associated TB unless a contraindi-
cation existed. This was continued after discharge by the
community clinics. However, data on this were not systemat-
ically recorded for the study. Demographic and clinical data
including a performance status measure (see Table S1,16,17
Supplemental Digital Content, http://links.lww.com/QAI/A717)
were recorded. Weight was measured using calibrated electronic
scales, and body mass index was calculated. Full blood count and
biochemistry were sent to the routine laboratory (see Table S2,
Supplemental Digital Content, http://links.lww.com/QAI/A717).
Venous blood was taken (after ﬂuid resuscitation and
without tourniquet) for point-of-care lactate, glucose mea-
surement, and study assays. All patients were given
intravenous ﬂuids after admission.
Pulmonary and/or extrapulmonary specimens were
taken for TB investigations depending on clinical presenta-
tion. If the diagnosis was not conﬁrmed by microscopy, an
empirical diagnosis could be made based on clinical and/or
radiological features, pending culture results, and according
to standard criteria for clinical diagnosis of TB.18,19 Ultra-
sound scans were performed in those with suspected pericar-
dial or abdominal TB.
Laboratory Methods
Specimens were examined using Ziehl–Neelsen staining,
locally, within 24 hours and cultured for mycobacteria in liquid
medium (MGIT; BD, Sparks, MD). Culture and drug suscep-
tibility testing was performed at the National Health Laboratory
Services laboratory in Umtata, South Africa. Venous lactate
and glucose were measured using a validated point-of-care
meter (Accutrend Plus; Roche Products, Roche Diagnostics
Division, United Kingdom) according to manufacturers’
instructions.20,21 The remainder of the venous blood was
centrifuged; plasma was frozen and stored. Assays for HIV
and CMV viral loads, LPS, I-FABP, and cryptococcal antigen
(CrAg) were performed retrospectively on these plasma speci-
mens at the University of Cape Town. HIV viral load was
measured on the Abbott RealTime HIV-1 platform (Abbott
Park, IL) and CMV viral load was measured on the Argene
CMV R-gene platform (Verniolle, France). The lower limit of
quantiﬁcation for HIV was 40 copies per milliliter and for
CMV was 150 copies per milliliter. CrAg was measured using
a lateral ﬂow assay (IMMY, Norman, OK). LPS was measured
using the Limulus amebocyte lysate assay (using the QCL-
1000 kit from Lonza, Walkersville, MD), with modiﬁcations as
previously described.22 Enzyme-linked immunosorbent assay
was used to measure I-FABP (Cusabio, Wuhan, China).
Follow-up and Outcome Ascertainment
Primary outcome was death within 8 weeks of initiating
TB treatment. Those discharged from hospital before 8 weeks
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were referred to primary care clinics for ongoing manage-
ment, including ART initiation, and contacted by telephone at
8 weeks. Readmission was a secondary outcome. We
attributed cause of death using 3 broad categories: pulmonary
TB alone, disseminated TB (evidence of miliary TB on chest
x-ray or extrapulmonary TB), or a concomitant diagnosis.
This was largely based on clinical diagnosis on admission,
but other aetiologies were documented during the study if
additional diagnostic information became available.
Definitions
Systemic inﬂammatory response syndrome (SIRS) was
deﬁned by the presence of at least 2 of the following:
tympanic temperature .38.3 or ,36°C; heart rate .90 beats
per minute; respiratory rate .20 breaths per minute; Glasgow
Coma Score (GCS) ,15 and point of care glucose .7.7
mmol/L in the absence of diabetes.23 White blood cell count
was not included in our deﬁnition, as it was not measured in
all participants on admission. Sepsis-induced tissue hypoper-
fusion was deﬁned as venous lactate $4 mmol/L.24
Statistical Methods
Data were analyzed using STATA v11 (Stata Corpora-
tion, College Station, TX). Fisher exact test was used for
categorical variables and Wilcoxon rank sum for continuous
variables. Logistic regression was used for multivariable
analysis and calculating adjusted odds ratios (aORs) for
death. Variables associated with death in the univariable
analysis (P # 0.05) were considered for inclusion in the
multivariable model and retained if a signiﬁcant association
remained after adjustment for other variables. To examine
correlation between biological markers, Spearman correlation
was performed on data collected for LPS, I-FABP, C-reactive
protein (CRP), and lactate.
Ethical Approval
Approval was granted by the University of Cape Town
Human Research Ethics Committee (reference number: 136/
2011). All participants provided written informed consent.
Those temporarily lacking capacity due to illness were invited
to consent or withdraw retrospectively once they regained
capacity. If such a patient died, then permission was obtained
from the Ethics Committee to include that patient’s data.
RESULTS
Patient Characteristics
One hundred individuals were enrolled: 99 were included
in the analysis and 1 was lost to follow-up (see Figure S1,
Supplemental Digital Content, http://links.lww.com/QAI/A717).
The median age was 32 years [interquartile range (IQR) 28–
41], and 40/99 (40%) were male. At the time of presentation,
the median time since HIV diagnosis was 3 months (IQR 0–
13). Median CD4 count taken ,6 months before or on
admission was 72 cells per cubic millimeter (IQR 24–148)
and median HIV viral load was 147,840 copies per milliliter
(IQR 9174–475,845) (n = 92). Of 99 patients, 31 had
previously been treated for TB.
Of 99 participants, 22 (22%) were on ART at enrollment:
6 on regimens including stavudine. Additional 7 patients had
previously taken ART, but had discontinued. After initiation of
TB treatment, data on ART were available on 77/99 patients;
51 of whom were on ART at 8 weeks. Of 99 patients, 35 (35%)
received antibiotics (not including cotrimoxazole prophylaxis)
other than TB treatment (see Figure S2, Supplemental Digital
Content, http://links.lww.com/QAI/A717), and 23 patients
were prescribed intravenous antibiotics on admission.
TB symptoms were present for .4 weeks in 75/99
patients. TB treatment was administered on the day of
admission in 47 patients. Sixty-four patients were diagnosed
with pulmonary TB, 23 with extra-pulmonary TB, and 12
with both.
Eighty-six patients had samples from any site examined
by microscopy. Of these, 55/86 were smear-negative and of
these, 34/55 were Mycobacterium tuberculosis–culture posi-
tive. Eighty patients had 1 sputum specimen cultured, 26 had
an extrapulmonary specimen cultured, and 13 had no speci-
mens cultured. TB was microbiologically conﬁrmed in 75
patients: from sputum (65 patients), pleural ﬂuid (3),
cerebrospinal ﬂuid (1), lymph node (4), ascitic ﬂuid (1), and
urine (1). Of these 75 patients, 63 were M. tuberculosis–
culture positive and only 12 were Ziehl–Neelsen-stain
positive. The remaining 24 were diagnosed clinico-
radiologically: 5 with compatible ultrasounds, 15 with
compatible chest radiographs, and 4 on clinical grounds
alone. Drug susceptibility testing was performed on 50/63
culture isolates. Forty-four isolates were susceptible to
rifampicin and isoniazid, 2 were resistant to isoniazid but
not rifampicin, and 4 were resistant to both drugs.
Routine bloods were taken a median of 1 day after
admission (IQR 0–3) and 1 day (IQR 0–4) after initiation of
TB treatment. Venous blood for study assays was taken
a median of 1 day (IQR 1–4) after admission and 1 day after
TB treatment initiation (IQR 0–3). Of 99 patients, 83 fulﬁlled
criteria for SIRS, 88/99 patients had a lactate$2 mmol/L, and
43/99 met the criteria for sepsis-induced hypoperfusion, with
a lactate $4 mmol/L. Of the 23 patients who were
commenced intravenous antibiotics, all had a lactate $2
mmol/L and 11 had a lactate of $4 mmol/L, suggesting that
intravenous antibiotics tended to be prescribed in patients
who were more critically ill.
Patient Outcomes and Predictors of Mortality
Of 99 patients, 32 died within 8 weeks, with 28/32
dying during the initial admission. There were 9 readmis-
sions, during which a further 4 patients died. The median
duration from TB treatment initiation to death was 8 days
(IQR 2.5–38.5). The median duration of initial admission was
16 days (IQR 10–35). Of the 28 who died during the ﬁrst
admission, 25 deaths were attributed to disseminated TB, 1 to
Kaposi sarcoma with pulmonary TB, and 2 deaths were
unexpected. Of 4 who died during readmission, 2 died of
cryptococcal meningitis, 1 died of drug-induced hepatitis, and
1 died of acute gastroenteritis with hypovolemic shock.
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The demographic, clinical, and laboratory parameters
that are continuous variables are summarized in Table S2 (see
Supplemental Digital Content, http://links.lww.com/QAI/A717)
comparing survivors with those who died.
The median CD4 cell count was lower for those who
died compared with those who survived [median 31/mm3 (IQR
13.5–119.5) and 80/mm3 (IQR 34–190), respectively; P =
0.004]. CD4 count was associated with mortality in univariable
analysis (Table 1), with OR 2.8 [95% conﬁdence interval (CI):
1.2 to 6.7] for CD4,50 versus$50 cells per cubic millimeter.
The median lactate in those who died was signiﬁcantly higher
at 5.5 versus 3.1 mmol/L in survivors (P , 0.001) (Fig. 1)
(see Table S2 and Figure S1, Supplemental Digital Content,
http://links.lww.com/QAI/A717). Venous lactate $4 mmol/L
was strongly associated with death [24/43 (56%) with lactate
$4 mmol/L died, compared with 8/56 (14%) with lactate ,4
mmol/L (OR 7.6, 95% CI: 2.9 to 19.8)]. Additional factors
associated with death in univariable analysis (Table 1) were
age $50 years (compared with age ,30 years, OR 7.7, and
95% CI: 1.2 to 46.9), GCS,15 (OR 4.5, 95% CI: 1.5 to 13.1),
performance score 4 compared with score of 2 (OR 19, 95%
CI: 5.7 to 64.2), creatinine $110 mmol/L (OR 3.8, 95% CI:
1.5 to 9.2), CRP $166 mmol/L (OR 2.5, 95% CI: 1.0 to 6.0),
hypoglycemia or hyperglycemia (OR 3.7, 95% CI: 1.5 to 8.8),
and albumin ,24 g/L (OR 6.0, 95% CI: 2.2 to 16.6). There
was a signiﬁcant correlation between CRP and lactate concen-
trations (r = 0.28, P = 0.005).
Of 6 individuals taking stavudine, 3 died (lactate range:
5.2–6.1 mmol/L). All had culture-conﬁrmed TB and their
death was believed to be due to disseminated TB. Twelve of
35 (35%) who received antibiotics other than TB treatment
and 20/64 (31%) who did not receive antibiotics died (P =
0.66). There was no signiﬁcant difference in HIV viral load
between those who died and those who survived. Plasma
CrAg was measured retrospectively: 4/99 were positive and 3
of these individuals died. Two of these 3, both of whom had
culture-conﬁrmed TB, died during readmission from crypto-
coccal meningitis. Further, an individual, whose plasma CrAg
was negative at enrollment, was readmitted with cryptococcal
meningitis 53 days after initiation of empiric TB treatment
and survived with treatment.
Of 97 patients, 23 (24%) had a detectable CMV viral
load with a median viral load of 500 copies per milliliter (IQR
250–1450) among these 23 patients. Eleven of 23 (48%) with
a detectable CMV viral load died compared with 21/74 (28%)
without a detectable CMV viral load (unadjusted OR 2.3,
95% CI: 0.88 to 6.1, P = 0.087).
In multivariable analysis (Table 2), venous lactate $4
mmol/L (aOR 9.8, 95% CI: 3.0 to 32.2; P , 0.001), age $50
years compared with age ,30 (aOR 7.7, 95% CI: 1.2 to 46.9;
P = 0.006), GCS ,15 (aOR 6.6, 95% CI: 1.5 to 29.6; P =
0.014), and CD4,50 cells per cubic millimeter (aOR 5.5, 95%
CI: 1.6 to 18.5; P = 0.006) were independently associated with
death. Performance status on admission was not included in the
model because of colinearity with low GCS. Sensitivity analysis
examining factors associated with mortality in those with
microbiologically proven TB (n = 75) continued to demonstrate
that lactate $4 mmol/L was independently associated with
death (aOR 6.6, 95% CI: 1.7 to 25.4; P , 0.006).
Intestinal Damage and
Microbial Translocation
The 32 individuals who died were matched to 32
survivors with similar CD4 cell counts (650 cells/mm3). For
28 of the controls, the CD4 cell count was matched within 20
cells per cubic millimeter of the corresponding case. The
median plasma LPS concentration for those who died was
signiﬁcantly higher than that of survivors, at 93 pg/mL (IQR
65.8–163.0) versus 57 pg/mL (IQR 0.0–100.3) (P = 0.026)
(Fig. 2). Median I-FABP in those who died was 131.5 pg/mL
(IQR 0.0–2033.0) compared with 0 pg/mL (IQR 0.0–6751.0)
in survivors (P = 0.002) (Fig. 3). Among these 64 patients
who had LPS and I-FABP assayed, there were no statistically
signiﬁcant correlations between LPS and lactate (r = 0.22, P =
0.079), between I-FABP and CRP (r = 0.21, P = 0.089),
between LPS and I-FABP (r = 0.03, P = 0.82), nor between
LPS and CRP (r = 20.01, P = 0.93).
DISCUSSION
In this study, mortality was 32% at 8 weeks. Factors
independently associated with mortality were raised venous
lactate, reduced admission GCS, low CD4 count, and older
age. The low median CD4 count at enrollment (median 72
cells/mm3) demonstrates profound immunosuppression; this
is consistent with a Ugandan study in which low baseline
CD4 count in HIV-associated TB predicted mortality.25
Reduced GCS is likely to reﬂect severe systemic illness or
central nervous system TB. Venous lactate $4 mmol/L was
the strongest predictor of death, with OR for death of 9.8
(95% CI: 3.0 to 32.2).
In a South African study of 1006 hospitalized HIV-
associated TB patients before widespread ART availability,
190/1006 (19%) died during hospital admission (half within
the ﬁrst 2 weeks) and further 60/1006 patients (6%) died after
discharge.6 The reasons for the high mortality of patients
hospitalized with HIV-associated TB despite TB treatment
and ART availability observed in our study and others6,7,26,27
have yet to be fully elucidated. Postmortem studies have
suggested that TB itself and bacterial and other coinfections
are important contributors.9,28 Opportunistic coinfections in
those with HIV-associated TB have been associated with
mortality.29 In our study, 4 individuals had detectable plasma
CrAg; 3 of whom died.
The prognostic role of venous lactate in HIV-associated
TB has not been studied previously. Bekker et al30 demon-
strated a rise in serum lactate and tumor necrosis factor-a in
the ﬁrst week of TB treatment in HIV-uninfected patients in
the 1990s. In our study, 83/99 presented with SIRS and 88/99
had a lactate $2 mmol/L, with higher venous lactate
concentration among those who died (median 5.5 mmol/L)
than survivors (median 3.1 mmol/L). Moreover, 43/99
patients had evidence of tissue hypoperfusion with lactate
$4 mmol/L. In a previous study of bacterial sepsis in the
United States, increased lactate was linearly associated with
mortality risk.31 We hypothesize that, in certain patients,
hyperlactatemia is a reﬂection of sepsis related to dissemi-
nated TB or superadded bacterial infection. Based on these
lactate ﬁndings, we suggest that the severity of illness of
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hospitalized HIV-associated TB patients is more akin to
patients with bacterial sepsis than out-patients with pulmo-
nary TB. We did not observe any association between
antibiotic prescription and mortality, but this analysis is
confounded by indication given the observational design of
our study. Therefore, we cannot conclude that antibiotics are
TABLE 1. Univariable Analysis of Categorical Exposure Variables and Association With Death
Variable Number in Category* Number (%) Died OR for Death 95% CI P
Age, yrs
18–29 31 7 (23%) 1 — —
30–39 41 14 (34%) 1.8 0.62 to 5.1 0.288
40–49 16 3 (19%) 0.8 0.17 to 3.6 0.761
$50 11 8 (73%) 9.1 1.9 to 44.0 0.006
Gender
Male 40 16 (40%) 1 —
Female 59 16 (27%) 0.6 0.24 to 1.3 0.181
CD4 cell count, cells/mm3
0–49 45 20 (44%) 2.8 1.2 to 6.7 0.020
50–650 54 12 (22%) 1 — —
ART status
Currently not on ART† 77 26 (34%) 1 —
Currently on ART 22 6 (27%) 0.7 0.28 to 2.1 0.567
Site of TB disease
Pulmonary 64 22 (34%) 1 —
Extrapulmonary 6 pulmonary 35 10 (29%) 0.8 0.31 to 1.9 0.556
Diagnosis conﬁrmed by culture and/or microscopy
Yes 75 23 (31%) 1 —
No (clinical/radiological diagnosis) 24 9 (38%) 1.2 0.72 to 1.9 0.534
Weeks from onset of TB symptoms to admission
#4 24 6 (25%) 1 —
.4 75 26 (35%) 1.59 0.56 to 4.5 0.381
Performance status score
1 and 2 47 12 (26%) 1 —
3 26 5 (19%) 1.4 0.38 to 4.8 0.633
4 26 20 (77%) 19 5.7 to 64.2 ,0.001
GCS
15 81 21 (26%) 1 —
#14 18 11 (61%) 4.5 1.5 to 13.1 0.006
Serum glucose (mmol/L) * abnormal glucose deﬁned by
hypoglycemia (#3.9 mmol/L) or hyperglycemia
($7.8 mmol/L)
Abnormal 41 20 (49%) 3.7 1.5 to 8.8 0.004
4.0–7.7 58 15 (15%) 1 —
Serum creatinine, mmol/L
39–109 64 14 (22%) 1 —
110–1166 35 18 (51%) 3.8 1.5 to 9.2 0.003
Serum albumin, g/L‡
12–23 54 26 (48%) 6.0 2.2 to 16.6 ,0.001
24–42 45 6 (13%) 1 —
Venous lactate, mmol/L
1.1–3.9 56 8 (14%) 1 —
4.0–7.8 43 24 (56%) 7.6 2.9 to 19.8 ,0.001
Serum CRP, mmol/L§
2.3–165.9 49 11 (22%) 1 —
166–497 50 21 (42%) 2.5 1 to 6 0.040
*Total number = 99 unless otherwise speciﬁed.
†This category includes 70 individuals naive to ART and 7 who had previously been on ART but stopped.
‡The median values of 23 g/L and 166 mmol/L, respectively, were used as a cut-off for comparison.
§Clinically relevant cut-offs were used for other parameters.
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not beneﬁcial in this patient group. This question can only be
adequately addressed by a randomized controlled trial.
In the nested case–control study, LPS and I-FABP
concentrations were higher in those who died than in
survivors, reﬂecting bacterial product translocation and
intestinal damage, respectively. The gastrointestinal tract is
a major site for HIV-1 replication and depletion of CD4
cells.32 Higher concentrations of plasma LPS and peptido-
glycan have been demonstrated in HIV-infected versus
uninfected individuals,32 providing evidence for microbial
product translocation, which has been associated with
immune activation during chronic HIV infection.12 Microbial
translocation in HIV-TB has not been extensively studied. In
a surprising ﬁnding from Uganda, circulating LPS concen-
trations were lower among HIV-TB patients with CD4 cell
counts ,350 cells per cubic millimeter compared with
healthy HIV-infected controls.33 The investigators attributed
this to elevations of LPS-binding proteins in HIV-TB but
were unable to conﬁrm this hypothesis. In the Ugandan study,
the association of LPS with mortality was not investigated.
In our study, the elevation of I-FABP and LPS levels in
individuals who died compared with those of survivors
supports the hypothesis that gut damage and microbial
translocation, respectively, may have resulted in immune
activation and contributed to sepsis syndrome and death. We
did not ﬁnd a signiﬁcant correlation between LPS and CRP.
However, measuring circulating LPS is challenging and may
not accurately quantify microbial translocation.34 The corre-
lation between LPS and other inﬂammatory markers was not
explored.
No signiﬁcant association was observed between CMV
viremia and mortality. A signiﬁcant association between
CMV viremia and mortality in HIV-infected out-patients
has been demonstrated previously.35 Our negative ﬁndings
may have been due to sample size and other, stronger, factors
driving mortality. Larger studies are warranted to assess the
contribution of CMV viremia to mortality in HIV-TB.
There were limitations. We did not include a control
group of patients with HIV but without active TB. Because
FIGURE 1. Venous lactate concentrations, comparing those
who died with those who survived. Median lactate for those
who died was 5.5 mmol/L (IQR 3.8–6.2) compared with the
median lactate for survivors, 3.1 mmol/L (IQR 2.2–4.1, P ,
0.001, Wilcoxon rank-sum test).









30–39 1.9 0.5 to 7.1 0.350
40–49 0.63 0.1 to 4.1 0.631
$50 7.7 1.2 to 46.9 0.028
Gender
Male 1
Female 0.9 0.29 to 2.7 0.810
CD4 cell count,
cells/mm3








4.0–7.8 9.8 3.0 to 32.2 ,0.001
*All ORs adjusted for age, gender, CD4 cell count, GCS, and venous lactate.
Creatinine, CRP, hemoglobin, albumin, and abnormal blood glucose were considered in
developing the ﬁnal model but were not statistically signiﬁcant in the multivariable
analysis and thus excluded from the ﬁnal model.
FIGURE 2. Nested case–control study comparing plasma LPS
concentrations of those who died (n = 32) with survivors (n =
32), matched for CD4 count (650 cells/mm3). Median plasma
LPS for those who died was 93 pg/mL (IQR 65.8–163) and in
survivors, 57 pg/mL (IQR 0–100.3, P = 0.026, Wilcoxon rank-
sum test).
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blood cultures were not available, we were unable to study
whether translocation of viable bacteria occurred or to
diagnose mycobacteraemia and its contribution to mortality.
The marker of monocyte response to bacterial LPS, the
coreceptor soluble CD14 (sCD14),22 has been shown in
previous studies to predict mortality in HIV22 and HIV-
associated TB.36 Toossi et al33 demonstrated that HIV-
associated TB patients with low CD4 counts did not display
a fall in circulating sCD14 levels after initiation of TB
treatment although patients with high CD4 counts did show
a fall. We could not measure this or other markers of
microbial product translocation, such as core endotoxin
antibody,22 because of limited sample volumes. Assessment
for additional coinfections relied mainly on clinical exami-
nation because of the paucity of diagnostic investigations
available. Furthermore, nearly a quarter of cases did not have
microbiological conﬁrmation of TB; however, raised venous
lactate continued to be an independent predictor of mortality
after sensitivity analysis of those individuals with proven TB.
Despite these limitations, these latter points reﬂect the health
service constraints in many high HIV-prevalence settings to
which our results are applicable.
CONCLUSIONS
Mortality after initiation of TB treatment in hospitalized
HIV-infected patients remains very high even in the era of
ART availability. Profound immunosuppression, impaired
consciousness, raised venous lactate, and older age were
independently associated with mortality. Plasma LPS and I-
FABP were higher in those who died than those who
survived, suggesting a role for gut barrier dysfunction and
microbial translocation. Larger studies further deﬁning the
pathophysiology and immediate causes of death in hospital-
ized HIV-associated TB patients are required. Additionally,
clinical trials of novel interventions aimed at improving acute
management of these severely ill patients, many of whom
have sepsis syndrome, are required.
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